Efficacy of Bee Venom as an Anti-Viral Therapy for HCV Genotype 4

Authors

  • Abd Elrazek M Ali Abd Elrazek

Keywords:

bee venom, HCV, traditional, therapy

Abstract

Use of traditional medicine is encouraged in many economically diverse countries when conventional medications fail. HCV prevalence is highest in Egypt at >10% of the general population, and China has the most people with HCV (29.8 million); approximately 52% of patients infected with HCV genotype 4 will develop chronic HCV. The use of interferon, currently the only approved therapy, is frustrating in many situations. Use of camel milk or drinking copious amounts of urine, moxibustion by fire, acupuncture and cupping, especially in the Saharan and Arabian areas, is currently popular in Egypt. Some traditional Egyptian medicine is related to Arabian, ancient Egyptian, or other religious beliefs. Most patients using traditional therapies show improvement over time in both clinical symptoms and laboratory results. Some showed SVR using Bee venom therapy.

How to Cite

Efficacy of Bee Venom as an Anti-Viral Therapy for HCV Genotype 4. (2014). Global Journal of Medical Research, 14(B3), 15-18. https://medicalresearchjournal.org/index.php/GJMR/article/view/570

References

Mohd Hanafiah, K Groeger, J Flaxman, A Wiersma, S (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. 57, 1333.

Behzad Hajarizadeh, Jason Grebely, Gregory Dore (2013) Epidemiology and natural history of HCV infection. 10(9), 553-562.

Kenny-Walsh E (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. 340, 1228.

M Vogt, T Lang, G Frösner (1999) Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. 341, 866.

A Shakil, C Conry-Cantilena, H Alter (1995) Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. 123, 330.

T Heintges, J Wands (1997) Hepatitis C virus: Epidemiology and transmission. 26(3), 521-526.

M Swain, M Lai, M Shiffman (2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. 139, 1593.

Marc Ghany, David Nelson, Doris Strader, David Thomas, Leonard Seeff (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. 54(4), 1433-1444.

P Ramachandran, A Fraser, K Agarwal (2012) UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. 35, 647.

Timothy Wilt, Areef Ishani, Gerold Stark, Roderick Macdonald, Joseph Lau, Cynthia Mulrow (1998) Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia. 280(18), 1604.

Vasilios Papastergiou, Dimitrios Dimitroulopoulos, Lamprini Skorda, Philippos Lisgos, Ioannis Ketikoglou, Nikolaos Kostas, Stylianos Karatapanis (2012) Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?. 84(8), 1217-1223.

Abdel-Moneim As Bamaga, M Shehab, G Abu-Elsaad, A Farahat, F (2012) HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate. 7(1), e29781.

A Shakil, Cathy Conry-Cantilena, Harvey Alter, Paul Hayashi, David Kleiner, Valeria Tedeschi, Krzysztof Krawczynski, Hari Conjeevaram, Richard Sallie, Adrian Bisceglie (1995) Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features. 123(5), 330-337.

Jae-Dong Lee, Su-Young Kim, Tae-Woo Kim, Sang-Hoon Lee, Hyung-In Yang, Doo-Ik Lee, Yun-Ho Lee (2004) Anti-inflammatory Effect of Bee Venom on Type II Collagen-Induced Arthritis. 32(03), 361-367.

Soo-Jung Kim, Ji-Hyun Park, Kyung-Hyun Kim, Woo-Ram Lee, Young-Chae Chang, Kwan-Kyu Park, Kwang-Gill Lee, Sang-Mi Han, Joo-Hong Yeo, Sok Pak (2010) Bee Venom Inhibits Hepatic Fibrosis Through Suppression of Pro-Fibrogenic Cytokine Expression. 38(05), 921-935.

Efficacy of Bee Venom as an Anti-Viral Therapy for HCV Genotype 4

Published

2014-06-13

How to Cite

Efficacy of Bee Venom as an Anti-Viral Therapy for HCV Genotype 4. (2014). Global Journal of Medical Research, 14(B3), 15-18. https://medicalresearchjournal.org/index.php/GJMR/article/view/570